心血管

订阅

MedSci主页 / 所有栏目 / 心血管

JACC：缺血性心脏病危险因素的控制与生存率

2018-10-31 MedSci MedSci原创

心血管缺血性心脏病生存率
关注

单个危险因素的控制可以提高稳定性缺血性心脏病（SIHD）的生存率，但是多重危险因素的控制是否会增加生存率尚不清楚。本研究的目的旨在评估大量危险因素的控制与SIHD患者生存率的关系。在2287名COURAGE临床试验的人群中，2102（92%）名患者接受有6大危险因素（收缩压、低密度脂蛋白胆固醇、抽烟、体育锻炼、饮食和BMI）的评估，主要终点事件是死亡率。经过平均6.8年时间的随访，473 (22.

单个危险因素的控制可以提高稳定性缺血性心脏病（SIHD）的生存率，但是多重危险因素的控制是否会增加生存率尚不清楚。本研究的目的旨在评估大量危险因素的控制与SIHD患者生存率的关系。

在2287名COURAGE临床试验的人群中，2102（92%）名患者接受有6大危险因素（收缩压、低密度脂蛋白胆固醇、抽烟、体育锻炼、饮食和BMI）的评估，主要终点事件是死亡率。经过平均6.8年时间的随访，473 (22.5%)名患者出现死亡，在单变量分析中，控制的危险因素越多，生存率的提高可能性就越大（p < 0.001），在多变量分析中，1年的最强预测因素是不抽烟、规律的体育锻炼和收缩压＜130mmHg。最终拥有4-6个危险因素比拥有0-1个危险因素的生存率更低（HR： 0.64； 95% Cl： 0.41 - 0.98）。

研究结果显示，危险因素控制的越多，稳定性缺血性心脏病患者的生存率就越高。


原始出处：

本文系梅斯医学(MedSci)原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893115, encodeId=19d8189311537, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat May 25 17:45:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854212, encodeId=9cbb18542125b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 01 16:45:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256681, encodeId=ddf4125668145, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318368, encodeId=fe70131836823, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326021, encodeId=92c5132602144, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2019-05-25 guihongzh

    #缺血性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1893115, encodeId=19d8189311537, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat May 25 17:45:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854212, encodeId=9cbb18542125b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 01 16:45:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256681, encodeId=ddf4125668145, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318368, encodeId=fe70131836823, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326021, encodeId=92c5132602144, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2019-10-01 hbwxf

    #JACC#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1893115, encodeId=19d8189311537, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat May 25 17:45:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854212, encodeId=9cbb18542125b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 01 16:45:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256681, encodeId=ddf4125668145, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318368, encodeId=fe70131836823, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326021, encodeId=92c5132602144, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2018-11-02 guoyibin

    #生存率#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1893115, encodeId=19d8189311537, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat May 25 17:45:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854212, encodeId=9cbb18542125b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 01 16:45:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256681, encodeId=ddf4125668145, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318368, encodeId=fe70131836823, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326021, encodeId=92c5132602144, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2018-11-02 ylz8403

    #缺血性心脏病#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1893115, encodeId=19d8189311537, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat May 25 17:45:00 CST 2019, time=2019-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854212, encodeId=9cbb18542125b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Oct 01 16:45:00 CST 2019, time=2019-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256681, encodeId=ddf4125668145, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318368, encodeId=fe70131836823, content=<a href='/topic/show?id=7b80e9367d2' target=_blank style='color:#2F92EE;'>#缺血性心脏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79367, encryptionId=7b80e9367d2, topicName=缺血性心脏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326021, encodeId=92c5132602144, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 02 01:45:00 CST 2018, time=2018-11-02, status=1, ipAttribution=)]
    2018-11-02 12498568m50暂无昵称

    #ACC#

    0

相关资讯

JACC：经皮导管主动脉瓣置换术在低外科风险患者中同样安全有效

经导管主动脉瓣置换术在低外科风险的严重主动脉瓣狭窄患者中安全有效，并发症更低，住院时间更短，30天死亡率为零。

JACC：主动脉瓣置换术后神经并发症的比较

主动脉瓣置换术后神经并发症会增加患者的死亡风险，经导管主动脉瓣置换术（TAVR）的开展在低外科风险的严重主动脉瓣狭窄患者中已经越来越普遍。本研究的目的旨在评估SURTAVI临床试验中的神经并发症。本研究将中度外科风险有临床症状的严重主动脉瓣狭窄患者（平均年龄79.8 ± 6.2岁，n=1660）1：1随机分至经皮导管主动脉瓣置换（TAVR）组和外科主动脉瓣置换（SAVR）组。分析结果显示，早期（术

盘点：JACC十月第五期研究一览

1. 经皮导管主动脉瓣置换术在低外科风险患者中同样安全有效DOI: 10.1016/j.jacc.2018.08.1033http://www.onlinejacc.org/content/72/18经导管主动脉瓣置换术（TAVR）目前是高风险外科主动脉瓣置换术（SAVR）有临床症状的严重主动脉瓣狭窄患者的标准治疗方法。本研究的目的旨在评估TAVR在低风险患者中的作用。本研究纳入了低风险TAV

JACC：经皮导管主动脉瓣置换术后原发性凝血障碍和主要出血并发症

围手术期和晚期（＞30天）出血是经导管主动脉瓣置换术后的主要并发症，本研究的目的旨在评估持续性原发性凝血障碍对晚期主要或危及生命的出血并发症（MLBCs）的影响。本研究中的出血事件是由VARC-2标准评估，持续性原发性凝血障碍定义为腺苷二磷酸的封闭时间（CT-ADP）＞180s。在372名接受经导管主动脉瓣置换术后30天的患者中，有42名（11.3%）患者发生了MLBCs，MLBCs的主要来源是胃

JACC：严重肢体缺血的外周动脉疾病患者的动脉病理变化

严重的肢体缺血（CLI）是外周动脉疾病（PAD）的主要并发症之一。本研究的目的旨在评估CLI患者膝盖上和膝盖下标本的PAD病理变化。本研究共纳入了95例外周动脉疾病患者的121个截肢标本，其中75例患者存在CLI，截肢标本的股动脉和腘动脉（FEM-POP）与膝下动脉（INFRA-POP）被单独进行病理分析。最终共分析了299条动脉，在239条来自CLI患者的动脉中，动脉粥样斑块在FEM-POP中更

CLIN CHEM：分析蛋白质组学发现的标志物和验证肝素给药对心血管生物标志物分析的混淆效应

一些血浆蛋白被认为是多种心血管疾病的标志物，但在独立的患者队列中情况却并非如此。这可能与药物对血浆蛋白浓度的干扰有关。研究人员使用蛋白质组学来鉴定血浆蛋白，这些蛋白的浓度随肝素的使用而改变，因此在使用肝素的情况下，它们作为生物标志物的评估可能会出现混淆。 研究人员使用了蛋白质组学的方法根据等压标签和nano-LC-MS / MS分析量化几百种蛋白质，个体血浆样本来自9例血管内超声随访12个月